Enzyme Replacement Therapy Market Analysis

  • Report ID: 4455
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Enzyme Replacement Therapy Market Analysis

Product (Agalsidase Beta, Imiglucerase, Velaglucerase Alfa, Idursulfase, Galsulfase, Laronidase)

The global enzyme replacement therapy market is segmented and analyzed for demand and supply by-products into agalsidase beta, imiglucerase, velaglucerase alfa, and others, out of which, the agalsidase beta segment is anticipated to garner the largest revenue by the end of 2037, backed by increasing prevalence of chronic disease in the population across the world owing to consumption of unhealthy food items and an engaged damaging lifestyle. Between 2000 and 2030, it was predicted that the number of Americans with chronic diseases would increase by around 45 million, or roughly 36%. Furthermore, the agalsidase segment held the second-largest market share in 2023. The increased cost and growing adoption of this medication in the treatment of Fabry disease are the principal factors for this segment's substantial market share.

Disease (Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis, Exocrine Pancreatic Insufficiency [EPI])

The global enzyme replacement therapy market is segmented and evaluated for demand and availability by disease into Gaucher disease, Fabry disease, Pompe disease, mucopolysaccharidosis, and exocrine pancreatic insufficiency [EPI], out of which, the exocrine pancreatic insufficiency segment captures the largest share in 2023 owing to the increasing incidence of this ailment amongst the general population. Furthermore, the high pervasiveness of exocrine pancreatic insufficiency among individuals suffering from chronic pancreatitis and cystic fibrosis contributes to a rise in the disease's patient group. This, in turn, contributes to this segment's supremacy over the forecast period. According to a Cleveland Clinic organization report, nearly 9 out of 10 infants with cystic fibrosis develop EPI during the first year. The remainder is in danger of developing EPI as children or adults.

Our in-depth analysis of the global enzyme replacement therapy market includes the following segments:

           By Product

  • Agalsidase Beta
  • Imiglucerase
  • Velaglucerase Alfa
  • Idursulfase
  • Galsulfase
  • Laronidase

          By Disease

  • Gaucher Disease
  • Fabry Disease
  • Pompe Disease
  • Mucopolysaccharidosis
  • Exocrine Pancreatic Insufficiency [EPI]

           By End-User

  • Hospitals
  • Infusion Centers & Home Healthcare Settings
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4455
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of enzyme replacement therapy is assessed at USD 12.03 billion.

The enzyme replacement therapy market size was valued at USD 11.42 billion in 2024 and is anticipated to reach USD 26.48 billion by the end of 2037, registering around 6.8% CAGR during the forecast period i.e., between 2025-2037. The market growth is driven by rise in prevalence of rare disease, growing government spending on healthcare infrastructure, growing cases of Pompe disease, and others.

Asia Pacific industry is set to dominate majority revenue share by 2037, owing to growing number of patient population suffering from rare disorders along with rising disposable income, growth in the healthcare sector, and an increase in government support in the region.

The major players in the market include BioMarin, Leadiant Biosciences, Inc., Pfizer Inc., Sanofi Aventis, AbbVie Inc., Takeda Pharmaceutical Company Limited, JCR Pharmaceutical Co., Ltd., AstraZeneca plc, Clinigen Limited, Teijin Limited.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample